Humalog (Insulin Lispro)

Humalog is prescribed for the control of hyperglycemia in patients with diabetes.

• Type 1 diabetes mellitus, as part of a basal‑bolus insulin regimen.
• Type 2 diabetes mellitus, when oral agents and basal insulin are insufficient.
• Management of high blood glucose during pregnancy (gestational diabetes) under medical supervision.
• Rapid correction of severe hyperglycemia or diabetic ketoacidosis when administered intravenously.
• Pre‑meal dosing to match carbohydrate intake and reduce post‑prandial glucose spikes.

• Insulin lispro binds to the α‑subunit of the insulin receptor on muscle, adipose and hepatic cells, activating the intrinsic tyrosine kinase. This triggers downstream signaling through the PI3K‑Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane and increasing glucose uptake. Simultaneously, hepatic gluconeogenesis is suppressed, lowering endogenous glucose production. The rapid onset of action results from the analog’s reduced tendency to form hexamers, allowing quicker absorption after injection.

Like all insulin preparations, Humalog may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia, presenting as sweating, tremor, hunger, or confusion.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy, including localized lipoatrophy or lipohypertrophy.
• Mild weight gain due to improved glycemic control.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or heart failure exacerbation in susceptible individuals.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.

Healthcare providers should consider several precautions before initiating Humalog therapy to ensure safe and effective use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose closely during initiation, dose adjustments, and periods of illness.
• Use caution in patients with a history of severe hypoglycemia or unawareness.
• Adjust doses during pregnancy, surgery, or when concomitant medications affect glucose metabolism.
• Educate patients on proper injection technique and rotation of sites to prevent lipodystrophy.
• Review cardiovascular status, especially in those with heart failure, before high‑dose use.

Humalog can interact with other agents that influence blood glucose levels or insulin pharmacokinetics, requiring careful management.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which may cause profound hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase insulin secretion.
• Thiazide diuretics and corticosteroids that raise blood glucose.
• Alcohol consumption, which can cause delayed hypoglycemia.
• Contrast media used in imaging studies, as they may affect insulin requirements.